Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Improving Dendritic Cell Cancer Vaccine Potency Using RNA Interference.

Sæbøe-Larssen S, Sioud M.

Methods Mol Biol. 2020;2115:249-258. doi: 10.1007/978-1-0716-0290-4_14.

PMID:
32006405
2.

Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine.

Sioud M, Nyakas M, Sæbøe-Larssen S, Mobergslien A, Aamdal S, Kvalheim G.

Case Rep Med. 2016;2016:9639585. doi: 10.1155/2016/9639585. Epub 2016 Jul 18.

3.

Immunosuppressive factor blockade in dendritic cells via siRNAs results in objective clinical responses.

Sioud M, Mobergslien A, Sæbøe-Larssen S.

Methods Mol Biol. 2015;1218:269-76. doi: 10.1007/978-1-4939-1538-5_16.

PMID:
25319657
4.

Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma.

Vik-Mo EO, Nyakas M, Mikkelsen BV, Moe MC, Due-Tønnesen P, Suso EM, Sæbøe-Larssen S, Sandberg C, Brinchmann JE, Helseth E, Rasmussen AM, Lote K, Aamdal S, Gaudernack G, Kvalheim G, Langmoen IA.

Cancer Immunol Immunother. 2013 Sep;62(9):1499-509. doi: 10.1007/s00262-013-1453-3. Epub 2013 Jul 2.

5.

A novel peptide carrier for efficient targeting of antigens and nucleic acids to dendritic cells.

Sioud M, Skorstad G, Mobergslien A, Sæbøe-Larssen S.

FASEB J. 2013 Aug;27(8):3272-83. doi: 10.1096/fj.12-224758. Epub 2013 May 13.

PMID:
23671272
6.

Silencing of indoleamine 2,3-dioxygenase enhances dendritic cell immunogenicity and antitumour immunity in cancer patients.

Sioud M, Saebøe-Larssen S, Hetland TE, Kaern J, Mobergslien A, Kvalheim G.

Int J Oncol. 2013 Jul;43(1):280-8. doi: 10.3892/ijo.2013.1922. Epub 2013 Apr 25.

PMID:
23620105
7.

Light-controlled modulation of gene expression using polyamidoamine formulations.

Bøe SL, Jørgensen JA, Longva AS, Lavelle T, Sæbøe-Larssen S, Hovig E.

Nucleic Acid Ther. 2013 Apr;23(2):160-5. doi: 10.1089/nat.2012.0413. Epub 2013 Mar 26.

PMID:
23530684
8.

Light-induced gene expression using messenger RNA molecules.

Bøe S, Saebøe-Larssen S, Hovig E.

Oligonucleotides. 2010 Feb;20(1):1-6. doi: 10.1089/oli.2009.0209.

PMID:
20038251
9.
10.

A full scale comparative study of methods for generation of functional Dendritic cells for use as cancer vaccines.

Jarnjak-Jankovic S, Hammerstad H, Saebøe-Larssen S, Kvalheim G, Gaudernack G.

BMC Cancer. 2007 Jul 3;7:119.

12.

Preclinical evaluation of autologous dendritic cells transfected with mRNA or loaded with apoptotic cells for immunotherapy of high-risk neuroblastoma.

Jarnjak-Jankovic S, Pettersen RD, Saebøe-Larssen S, Wesenberg F, Olafsen MR, Gaudernack G.

Cancer Gene Ther. 2005 Aug;12(8):699-707.

PMID:
15846368
13.

Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination.

Kyte JA, Kvalheim G, Aamdal S, Saebøe-Larssen S, Gaudernack G.

Cancer Gene Ther. 2005 Jun;12(6):579-91.

PMID:
15818380
14.

Evaluation of dendritic cells loaded with apoptotic cancer cells or expressing tumour mRNA as potential cancer vaccines against leukemia.

Jarnjak-Jankovic S, Pettersen RD, Saebøe-Larssen S, Wesenberg F, Gaudernack G.

BMC Cancer. 2005 Feb 18;5:20.

15.

Development of a clinical grade procedure for generation of mRNA transfected dendritic cells from purified frozen CD34(+) blood progenitor cells.

Mu LJ, Lazarova P, Gaudernack G, Saeboe-Larssen S, Kvalheim G.

Int J Immunopathol Pharmacol. 2004 Sep-Dec;17(3):255-63.

PMID:
15461859
16.

A protocol for generation of clinical grade mRNA-transfected monocyte-derived dendritic cells for cancer vaccines.

Mu LJ, Gaudernack G, Saebøe-Larssen S, Hammerstad H, Tierens A, Kvalheim G.

Scand J Immunol. 2003 Nov;58(5):578-86.

17.

HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes.

Gjertsen MK, Saeterdal I, Saebøe-Larssen S, Gaudernack G.

J Mol Med (Berl). 2003 Jan;81(1):43-50. Epub 2002 Nov 13.

PMID:
12545248
18.

Nonviral and viral gene transfer into different subsets of human dendritic cells yield comparable efficiency of transfection.

Lundqvist A, Noffz G, Pavlenko M, Saebøe-Larssen S, Fong T, Maitland N, Pisa P.

J Immunother. 2002 Nov-Dec;25(6):445-54.

PMID:
12439342
19.
20.

Ribosomal protein insufficiency and the minute syndrome in Drosophila: a dose-response relationship.

Saebøe-Larssen S, Lyamouri M, Merriam J, Oksvold MP, Lambertsson A.

Genetics. 1998 Mar;148(3):1215-24.

21.
22.

A novel Drosophila Minute locus encodes ribosomal protein S13.

Saebøe-Larssen S, Lambertsson A.

Genetics. 1996 Jun;143(2):877-85.

23.

Evolution of the Group 1 late embryogenesis abundant (Lea) genes: analysis of the Lea B19 gene family in barley.

Stacy RA, Espelund M, Saebøe-Larssen S, Hollung K, Helliesen E, Jakobsen KS.

Plant Mol Biol. 1995 Sep;28(6):1039-54.

PMID:
7548822
24.

A Drosophila third chromosome Minute locus encodes a ribosomal protein.

Andersson S, Saebøe-Larssen S, Lambertsson A, Merriam J, Jacobs-Lorena M.

Genetics. 1994 Jun;137(2):513-20.

25.

Late embryogenesis-abundant genes encoding proteins with different numbers of hydrophilic repeats are regulated differentially by abscisic acid and osmotic stress.

Espelund M, Saebøe-Larssen S, Hughes DW, Galau GA, Larsen F, Jakobsen KS.

Plant J. 1992 Mar;2(2):241-52. Erratum in: Plant J 1992 Jul;2(4):639.

Supplemental Content

Loading ...
Support Center